Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27Kip1

Cancer Research

Volumn 63, Issue 11, 2003, Pages 2977-2981

  Kouvaraki, Maria A ^a   Rassidakis, George Z ^b   Tian, Ling ^a   Kumar, Rakesh ^a   Kittas, Christos ^b   Claret, François Xavier ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; JUN ACTIVATION DOMIAN BINDING PROTEIN A; PROTEIN P27; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL CYCLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME DEGRADATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ADENOVIRIDAE; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; PEPTIDE HYDROLASES; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0037567489     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Claret. F. X., Hibi, M., Dhut, S., Toda, T., and Karin, M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature (Lond.), 383: 453-457, 1996.
2. Chamovitz, D. A., and Segal, D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep., 2: 96-101, 2001.
3. Schwechheimer, C., and Deng, X. W. COP9 signalosome revisited: a novel mediator of protein degradation. Trends Cell Biol., 11: 420-426, 2001.
4. Kip1 is instigated by Jab1. Nature (Lond.), 398: 160-165, 1999.
5. 1-phase progression. Genes Dev., 13: 1501-1512, 1999.
6. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
7. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Wash. DC), 269: 682-685, 1995.
8. Kip1. Genes Dev., 11: 1464-1478, 1997.
9. Vlach, J., Hennecke, S., and Amati, B. Phosphorylation-dependent degradation of the cyclin-dependent kinaseu inhibitor p27. EMBO J., 16: 5334-5344, 1997.
10. Montagnoli, A., Fiore, F., Eytan, E., Carrano, A. C., Draetta, G. F., Hershko, A., and Pagano, M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev., 13: 1181-1189, 1999.
11. 1 and S phase. Nature (Lond.), 413: 323-327, 2001.
12. Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J. Biol. Chem., 277: 2302-2310, 2002.
13. Kip1 protein and Jun activation domain-binding protein 1 in human pituitary tumors. J. Clin. Endocrinol. Metab., 87: 2635-2643, 2002.
14. Kip1 and poor prognosis in epithelial ovarian tumors. Clin. Cancer Res., 7: 4130-4135, 2001.
15. Kouvaraki, M., Gorgoulis, V. G., Rassidakis, G. Z., Liodis, P., Markopoulos, C., Gogas, J., and Kittas, C. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors. Cancer (Phila.), 94: 2454-2465, 2002.
16. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
17. Barnes, C. J., Li, F., Mandal, M., Yang, Z., Sahin, A. A., and Kumar, R. Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. Cancer Res., 62: 1251-1255, 2002.
18. Sanchez-Beato, M., Camacho, F. I., Martinez-Montero, J. C., Saez, A. I., Villuendas, R., Sanchez-Verde, L., Garcia, J. F., and Piris, M. A. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression, p27/KIP1-cyclin D3 colocalization in tumor cells. Blood, 94: 765-772, 1999.
19. Seeger, M., Kraft, R., Ferrell, K., Bech-Otschir, D., Dumdey, R., Schade, R., Gordon, C., Naumann, M., and Dubiel, W. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J., 12: 469-478, 1998.
20. Kleemann, R., Hausser, A., Geiger, G., Mischke, R., Burger-Kentischer, A., Flieger, O., Johannes, F. J., Roger, T., Calandra, T., Kapurniotu, A., Grell, M., Finkelmeier, D., Brunner, H., and Bernhagen, J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature (Lond.), 408: 211-216, 2000.
21. Bianchi, E., Denti, S., Granata, A., Bossi, G., Geginat, J., Villa, A., Rogge, L., and Pardi, R. Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature (Lond.), 404: 617-621, 2000.
22. Wan, M., Cao, X., Wu, Y., Bai, S., Wu, L., Shi, X., and Wang, N. Jab1 antagonizes TGF-β signaling by inducing Smad4 degradation. EMBO Rep., 3: 171-176, 2002.
23. Bae, M. K., Ahn, M. Y., Jeong, J. W., Bae, M. H., Lee, Y. M., Bae, S. K., Park, J. W., Kim, K. R., and Kim, K. W. Jab1 interacts directly with HIF-1 α and regulates its stability. J. Biol. Chem., 277: 9-12, 2002.
24. Lu, C., Li, Y., Zhao, Y., Xing, G., Tang, F., Wang, Q., Sun, Y., Wei, H., Yang, X., Wu, C., Chen, J., Guan, K. L., Zhang, C., Chen, H., and He, F. Intracrine hepatopoietin potentiates AP-1 activity through JAB1 independent of MAPK pathway. FASEB J., 16: 90-92, 2002.
25. Smith, L. M., Wise, S. C., Hendricks, D. T., Sabichi, A. L., Bos, T., Reddy, P., Brown, P. H., and Birrer, M. J. c-Jun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene, 18: 6063-6070, 1999.
26. Gee, J. M., Barroso, A. F., Ellis, I. O., Roberston, J. F., and Nicholson, R. I. Biological and clinical association of c-Jun activation in human breast cancer. Int. J. Cancer, 89: 177-186, 2000.
27. Ozanne, B. W., McGarry, L., Spence, H. J., Johnston, I., Winnie, J., Meagher, L., and Stapleton, G. Transcriptional regulation of cell invasion: AP-1 regulation of a mulqtigenic invasion programme. Eur. J. Cancer, 36: 1640-1648, 2000.